ATE446298T1 - Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen - Google Patents
Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungenInfo
- Publication number
- ATE446298T1 ATE446298T1 AT02795691T AT02795691T ATE446298T1 AT E446298 T1 ATE446298 T1 AT E446298T1 AT 02795691 T AT02795691 T AT 02795691T AT 02795691 T AT02795691 T AT 02795691T AT E446298 T1 ATE446298 T1 AT E446298T1
- Authority
- AT
- Austria
- Prior art keywords
- adenosine
- receptors
- applications
- compounds
- compounds specific
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 title abstract 2
- 229960005305 adenosine Drugs 0.000 title abstract 2
- 101150046889 ADORA3 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33527301P | 2001-11-30 | 2001-11-30 | |
| US33727401P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/038055 WO2003048120A2 (en) | 2001-11-30 | 2002-11-27 | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446298T1 true ATE446298T1 (de) | 2009-11-15 |
Family
ID=26989631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02795691T ATE446298T1 (de) | 2001-11-30 | 2002-11-27 | Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7504407B2 (de) |
| EP (2) | EP2050751A1 (de) |
| JP (1) | JP2005529062A (de) |
| AT (1) | ATE446298T1 (de) |
| AU (1) | AU2002360436A1 (de) |
| CA (1) | CA2468673C (de) |
| DE (1) | DE60234118D1 (de) |
| DK (1) | DK1450811T3 (de) |
| WO (1) | WO2003048120A2 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0103836A3 (en) * | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| BR0115847A (pt) * | 2000-12-01 | 2004-02-25 | Osi Pharm Inc | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos |
| UA74228C2 (uk) * | 2000-12-01 | 2005-11-15 | Осі Фармасьютікалз, Інк. | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ, СПЕЦИФІЧНІ ДО АДЕНОЗИНОВОГО A<sub>1</sub>, A<sub>2А</sub> І A<sub>3</sub> РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
| DE60236458D1 (de) * | 2001-12-20 | 2010-07-01 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도 |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US20080051393A1 (en) * | 2006-05-01 | 2008-02-28 | Eastern Virginia Medical School | Novel cannabinoids and methods of use |
| AU2007248760A1 (en) * | 2006-05-01 | 2007-11-15 | Eastern Virginia Medical School | Novel cannabinoids and methods of use |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| TWI443337B (zh) * | 2008-10-10 | 2014-07-01 | Ct Hospitalier Universitaire Sainte Justine | 用於脊柱側彎之分類及診斷的方法 |
| DE102008052891A1 (de) * | 2008-10-23 | 2010-05-20 | Ewald Dörken Ag | Befestigungselement für genoppte Kunststoffbahnen |
| US9199102B2 (en) | 2009-07-21 | 2015-12-01 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
| AU2014214561C1 (en) | 2013-02-11 | 2019-01-17 | Mitokinin, Inc. | Compositions and methods for treating neurodegenerative diseases |
| EA027879B1 (ru) | 2013-02-22 | 2017-09-29 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| WO2018237145A1 (en) | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| EP4121431A1 (de) * | 2021-01-09 | 2023-01-25 | Bugworks Research, Inc. | Diaminopyrazolo[1,5-a pyrimidin-6-carbonitril-verbindungen als adenosin 2a rezeptor und adenosin 2b rezeptor antagonist |
| KR20230158044A (ko) | 2021-03-18 | 2023-11-17 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US409930A (en) * | 1889-08-27 | Knockdown table | ||
| US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
| GB915304A (en) | 1958-03-13 | 1963-01-09 | Wellcome Found | Pyrrolo[2,3-d]pyrimidine derivatives |
| US3910913A (en) | 1969-11-04 | 1975-10-07 | American Home Prod | 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives |
| US4550022A (en) | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| DE3145287A1 (de) | 1981-11-14 | 1983-05-19 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| IN157280B (de) | 1983-07-15 | 1986-02-22 | Hoechst India | |
| GB8729994D0 (en) | 1987-12-23 | 1988-02-03 | Glaxo Group Ltd | Chemical compounds |
| IL89028A0 (en) | 1988-01-29 | 1989-08-15 | Lilly Co Eli | Quinoline,quinazoline and cinnoline derivatives |
| AU641183B2 (en) | 1989-09-19 | 1993-09-16 | Teijin Limited | Pyrrolo(2,3-d)pyrimidine derivative, process for preparing the same, and pharmaceutical preparation comprising the derivative as active ingredient |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5208240A (en) | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5516894A (en) | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
| PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| BR9307646A (pt) | 1992-12-17 | 1999-05-25 | Pfizer | Pirrolopirimidinas como antagonistas de crf |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| CA2155130C (en) | 1993-02-26 | 1994-09-01 | Janice M Hitchcock | Xanthine derivatives as adenosine a1 receptor antagonists |
| JPH08511241A (ja) | 1993-04-08 | 1996-11-26 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ２−アミノイミダゾールとアルデヒドから４−および／または５−（ジ）置換された２−アミノイミダゾールを合成するための方法 |
| WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| EP0738149B1 (de) | 1994-01-10 | 2006-11-29 | Teva Pharmaceutical Industries, Ltd. | 1-aminoindanderivate und zusammensetzungen hiervon |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| AU697134B2 (en) | 1994-01-26 | 1998-09-24 | Novartis Ag | Modified oligonucleotides |
| US5646156A (en) | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| US5877180A (en) | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| WO1996019478A1 (en) | 1994-12-19 | 1996-06-27 | Novartis Ag | 6'-substituted carbocyclic nucleosides |
| EP0729758A3 (de) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidine und Pyrrolopyrimidine zur Behandlung von neuronalen und anderen Krankheiten |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5646130A (en) | 1995-06-30 | 1997-07-08 | Ocean University Of Oingdao | Low molecular weight sulfated polysaccharides and uses thereof |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| US5780450A (en) | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997033879A1 (en) | 1996-03-15 | 1997-09-18 | Merck & Co., Inc. | Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
| JPH09291089A (ja) | 1996-04-26 | 1997-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な５−チアゾリルウラシル誘導体又はその塩 |
| WO1997047601A1 (en) | 1996-06-11 | 1997-12-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| US5780481A (en) | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
| PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| EP0923287A4 (de) | 1996-08-30 | 2001-08-01 | Lilly Co Eli | Nichtklassische pyrrolo(2,3-d)pyrimidin antifolate |
| US5786360A (en) | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| AU7890598A (en) | 1996-12-27 | 1998-07-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
| FR2763334A1 (fr) | 1997-05-13 | 1998-11-20 | Lipha | Derives anthraniliques |
| JP2002505687A (ja) | 1997-06-18 | 2002-02-19 | ディスカバリー セラピューティクス，インコーポレイテッド | 脈管再生手順の後の再狭窄を防止するための組成物および方法 |
| CA2296485A1 (en) | 1997-07-29 | 1999-02-11 | Medco Research, Inc. | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| US6151484A (en) | 1997-08-08 | 2000-11-21 | Ericsson Inc. | Communications apparatus and methods for adaptive signal processing based on mobility characteristics |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6686366B1 (en) * | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6878716B1 (en) * | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
| US20020015967A1 (en) | 1998-06-02 | 2002-02-07 | Lauren Silverman | Functional expression of adenosine receptors in yeast |
| HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| EP1096975B1 (de) | 1998-07-16 | 2005-03-16 | The Trustees Of The University Of Pennsylvania | Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks |
| US6463687B1 (en) * | 1998-09-25 | 2002-10-15 | Edward J. Dorstewitz | Collapsible safety sign |
| US6680332B1 (en) * | 1999-06-04 | 2004-01-20 | Euro-Celtique S.A. | Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| ES2269217T3 (es) * | 1999-12-02 | 2007-04-01 | Osi Pharmaceuticals, Inc. | Compuestos especificos para los receptores a1, a2a y a3 de adenosina y sus usos. |
| US6664252B2 (en) * | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US6465456B2 (en) | 2000-06-29 | 2002-10-15 | Bristol-Myers Squibb Company | Isoxazolinone antibacterial agents |
| US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| BR0115847A (pt) | 2000-12-01 | 2004-02-25 | Osi Pharm Inc | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos |
| US6680324B2 (en) * | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도 |
| DE60236458D1 (de) * | 2001-12-20 | 2010-07-01 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
| EA012926B1 (ru) | 2001-12-20 | 2010-02-26 | Оси Фармасьютикалз, Инк. | Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| JP4074160B2 (ja) * | 2002-08-28 | 2008-04-09 | 富士通株式会社 | 半導体装置の製造方法及びレジストパターンの形成方法 |
| JP2006518390A (ja) | 2003-02-19 | 2006-08-10 | エンダシア，インコーポレイテッド | Ａ１アデノシンレセプターアンタゴニスト |
| CN103309150B (zh) | 2013-06-26 | 2015-06-17 | 上海华力微电子有限公司 | 版图数据的处理方法 |
| US9816053B2 (en) | 2015-03-26 | 2017-11-14 | Melynda S DelCotto | Candle having a wooden wick with figured grain |
| US9804595B1 (en) | 2015-06-19 | 2017-10-31 | Samuel E. Denard | Control system for communicating with and controlling operations of a vehicle |
-
2002
- 2002-11-27 JP JP2003549312A patent/JP2005529062A/ja active Pending
- 2002-11-27 WO PCT/US2002/038055 patent/WO2003048120A2/en not_active Ceased
- 2002-11-27 AU AU2002360436A patent/AU2002360436A1/en not_active Abandoned
- 2002-11-27 EP EP09002106A patent/EP2050751A1/de not_active Withdrawn
- 2002-11-27 US US10/497,451 patent/US7504407B2/en not_active Expired - Fee Related
- 2002-11-27 DK DK02795691.1T patent/DK1450811T3/da active
- 2002-11-27 AT AT02795691T patent/ATE446298T1/de not_active IP Right Cessation
- 2002-11-27 CA CA2468673A patent/CA2468673C/en not_active Expired - Fee Related
- 2002-11-27 DE DE60234118T patent/DE60234118D1/de not_active Expired - Lifetime
- 2002-11-27 EP EP02795691A patent/EP1450811B1/de not_active Expired - Lifetime
-
2008
- 2008-08-27 US US12/231,029 patent/US20090192177A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7504407B2 (en) | 2009-03-17 |
| DK1450811T3 (da) | 2010-02-15 |
| WO2003048120A2 (en) | 2003-06-12 |
| EP2050751A1 (de) | 2009-04-22 |
| AU2002360436A1 (en) | 2003-06-17 |
| AU2002360436A8 (en) | 2003-06-17 |
| DE60234118D1 (de) | 2009-12-03 |
| EP1450811A4 (de) | 2005-11-16 |
| JP2005529062A (ja) | 2005-09-29 |
| US20050090513A1 (en) | 2005-04-28 |
| CA2468673A1 (en) | 2003-06-12 |
| US20090192177A1 (en) | 2009-07-30 |
| CA2468673C (en) | 2011-01-25 |
| EP1450811A2 (de) | 2004-09-01 |
| WO2003048120A3 (en) | 2003-09-04 |
| EP1450811B1 (de) | 2009-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60234118D1 (de) | Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen | |
| AP1893A (en) | Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof | |
| DK1246623T3 (da) | Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf | |
| PA8521501A1 (es) | Ligandos para receptores de melanocortina | |
| TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
| JP2007523178A5 (de) | ||
| BR0208636A (pt) | Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com infncia | |
| BRPI0411699A (pt) | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos | |
| BR112021025537A2 (pt) | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica | |
| CY1114965T1 (el) | Cpg ολιγονουκλεοτιδια χρησιμοποιουμενα για ενισχυση της δραστικοτητας στεροειδων σε εναν εξαρτημενο απο στεροειδη ασθενη | |
| ATE302770T1 (de) | Benzimidazolverbindungen die nociceptinrezeptoraffinität haben | |
| DOP2002000429A (es) | Imidazotriazinas | |
| UY27258A1 (es) | Derivados de dihidro-benzo b 1, 4 diazepin-2-ona como antagonistas ii mglur2 | |
| DE60230773D1 (de) | Harnstoff-derivate als vanilloid-rezeptor-antagonisten für die schmerzbehandlung | |
| BR0209812A (pt) | Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas | |
| EE200100179A (et) | Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks | |
| DE60231386D1 (de) | Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson | |
| BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
| CY1110368T1 (el) | Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη | |
| BRPI0608287A2 (pt) | agente endoparasiticida | |
| BR0309684A (pt) | O tratamento de dor com ifendropil | |
| PL1612210T3 (pl) | Nowe analogi nitrobenzylotioinozyny | |
| DE50210279D1 (de) | Screeningverfahren mit bnpi und dnpi | |
| ITRM20010136A0 (it) | Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma. | |
| ES1050463Y (es) | Dispositivo terapeutico para el tratamiento de sintomas ocasionados por enfermedades. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |